环氧合酶-2与亚临床动脉粥样硬化关系的临床研究

Clinical research of cyclooxygenase-2 and subclinical atherosclerosis relations

目的:探讨亚临床动脉粥样硬化(AS)患者血清或血浆中环氧合酶Ⅱ(COX-2)的水平;COX-2水平与亚临床AS影响因素的关系;COX-2抑制剂对预防AS有潜在的临床应用价值。方法:应用酶联免疫法(ELISA)检测亚临床AS患者100例和40名健康人为正常对照组的血浆COX-2水平,并结合临床资料进行分析。结果:亚临床AS组COX-2水平[(10.84±3.11)U/L]明显高于正常对照组[(6.97±1.25)U/L],两者比较差异有统计学意义(P<0.01)。结论:COX-2水平与亚临床AS水平有明显相关性,测定血浆COX-2活性可作为亚临床AS的诊断、预后判断的参考指标;临床进行早期干预,拮抗COX-2的治疗可能有助于降低心血管意外发作风险。

Objective： To explore subclinical atherosclerosis（AS） patients with serum or plasma cyclooxygenase Ⅱ（COX-2） level; COX-2 levels and sub-clinical factors influence the relationship between AS; COX-2 inhibitors AS prevention potential clinical value. Methods： Enzyme-linked immunosorbent assay（ELISA） detection of subclinical AS 100 patients and 40 healthy control human plasma levels of COX-2, and combined with clinical data analysis. Results： The sub-clinical levels of COX-2 AS group[（10.84±3.11） U/L], significantly higher than the control group[（6.97±1.25） U/L], the difference was statistically significant（P0.01）. Conclusion： COX-2 AS level and sub-clinical level of significant relevance, COX-2 activity in plasma can be used as sub-clinical diagnosis of AS and prognosis of reference; clinical early intervention, treatment of COX-2 antagonism may help reduce the risk of cardiovascular accidents in the attack.